However, the utility of CA-125 as a diagnostic marker is limited as it detects approximately 50% of patients with stage I ovarian cancer and cannot distinguish between a benign and a malignant adnexal mass [6,7]. This evidence concerns the gene MUC16 and ovarian cancer.